

CITATION REPORT

List of articles citing

Novel mutations of the MET proto-oncogene in papillary renal carcinomas

DOI: 10.1038/sj.onc.1202547
Oncogene, 1999, 18, 2343-50.

Source: <https://exaly.com/paper-pdf/30431199/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
470	Pseudotumour cerebri syndrome due to cryptococcal meningitis. 1997 , 62, 96-8		16
469	Classification of renal cell cancer based on (cyto)genetic analysis. 1999 , 128, 51-61		10
468	Hereditary papillary renal carcinoma: pathology and pathogenesis. 1999 , 128, 11-27		4
467	HISTOPATHOLOGY AND MOLECULAR GENETICS OF RENAL TUMORS: TOWARD UNIFICATION OF A CLASSIFICATION SYSTEM. <i>Journal of Urology</i> , 1999 , 162, 1246-1258	2.5	142
466	Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. 1999 , 155, 517-26		199
465	Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. 2000 , 53, 137-44		39
464	Bibliography Current World Literature. 2000 , 12, B79-B133		
463	Current World Literature. <i>Current Opinion in Urology</i> , 2000 , 10, 499-537	2.8	
462	The expression of Met/hepatocyte growth factor receptor gene in giant cell tumors of bone and other benign musculoskeletal tumors. 2000 , 184, 191-6		13
461	Signature-based analysis of MET proto-oncogene mutations using DHPLC. <i>Human Mutation</i> , 2000 , 16, 68-76	4.7	33
460	Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. <i>Oncogene</i> , 2000 , 19, 1354-61	9.2	23
459	Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. <i>Oncogene</i> , 2000 , 19, 1547-55	9.2	284
458	Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. <i>Oncogene</i> , 2000 , 19, 2996-3002	9.2	26
457	A novel germ line juxtamembrane Met mutation in human gastric cancer. <i>Oncogene</i> , 2000 , 19, 4947-53	9.2	290
456	Inherited epithelial tumors of the kidney: old and new diseases. 2000 , 10, 313-8		15
455	New treatment approaches for metastatic renal cell carcinoma. 2000 , 2, 417-22		5
454	Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. 2000 , 21, 1507-1512		3

453	Precancerous Lesions in the Kidney. 2000 , 34, 136-165		4
452	Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. 2000 , 21, 1507-1512		61
451	Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. 2000 , 261, 229-38		79
450	SPORADIC BILATERAL PAPILLARY RENAL CARCINOMA EXHIBITING C-MET MUTATION IN THE LEFT KIDNEY TUMOR. <i>Journal of Urology</i> , 2000 , 163, 1241-1242	2.5	3
449	Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. 2001 , 5, 101-6		28
448	Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. 2001 , 32, 590-5		273
447	Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. 2001 , 2, 41-55		55
446	The Receptor Tyrosine Kinases. 2001 , 10, 271-288		34
445	Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. 2001 , 44, 32-43		55
444	Random mutagenesis-PCR to introduce alterations into defined DNA sequences for validation of SNP and mutation detection methods. <i>Human Mutation</i> , 2001 , 17, 210-9	4.7	12
443	MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. 2001 , 189, 285-90		42
442	Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation. <i>Oncogene</i> , 2001 , 20, 7610-23	9.2	25
441	Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. 2001 , 21, 5857-68		141
440	Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. 2001 , 276, 14308-14		78
439	Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation. 2002 , 20, 1544-1550		33
438	Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. 2002 , 20, 2376-81		398
437	Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. 2002 , 13, 1847-54		215
436	Renal cancer: molecular mechanisms and newer therapeutic options. 2002 , 11, 37-42		71

435	Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. 2002 , 161, 997-1005		60
434	Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. 2002 , 13, 41-59		341
433	Biological Significance of C-met Over Expression in Papillary Renal Cell Carcinoma. <i>Journal of Urology</i> , 2002 , 168, 51-55	2.5	60
432	Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. 2002 , 20, 1544-50		78
431	Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. 2002 , 2, 157-64		705
430	Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. 2002 , 35, 359-64		22
429	Genetic progression of renal cell carcinoma. 2002 , 441, 320-7		15
428	Expression and localization of HGF and met in Wilms tumours. 2002 , 196, 76-84		20
427	K252a inhibits the oncogenic properties of Met, the HGF receptor. <i>Oncogene</i> , 2002 , 21, 4885-93	9.2	131
426	Scatter-factor and semaphorin receptors: cell signalling for invasive growth. 2002 , 2, 289-300		630
425	c-Met: structure, functions and potential for therapeutic inhibition. 2003 , 22, 309-25		379
424	Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. 2003 , 3, 347-61		1111
423	Molecular and cellular biology of small cell lung cancer. 2003 , 30, 57-71		54
422	Overexpression of KIT in chromophobe renal cell carcinoma. <i>Oncogene</i> , 2003 , 22, 847-52	9.2	134
421	Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. <i>Oncogene</i> , 2003 , 22, 8519-23	9.2	54
420	The genetic basis of renal cell carcinoma. 2003 , 30, 437-54, vii		34
419	Molecular targeting of VHL gene pathway in clear cell kidney cancer. <i>Journal of Urology</i> , 2003 , 170, 593-4.5	4.5	31
418	The genetic basis of cancer of the kidney. <i>Journal of Urology</i> , 2003 , 170, 2163-72	2.5	388

417	Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo. 2003 , 302, 892-7	12
416	Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. 2003 , 278, 29352-8	37
415	A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. 2003 , 40, e97	36
414	Renal cell carcinoma: a priority malignancy for development and study of novel therapies. 2003 , 21, 1193-4	31
413	Studying cancer families to identify kidney cancer genes. 2003 , 54, 217-33	54
412	Renal Cell Carcinoma: The Human Disease. 2003 , 451-460	
411	Prostate cancer and the met hepatocyte growth factor receptor. 2004 , 91, 31-67	69
410	Hereditary papillary renal carcinoma type I. 2004 , 4, 855-68	77
409	Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail. 2004 , 279, 19732-8	47
408	Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. 2004 , 101, 17198-203	90
407	Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. 2004 , 64, 6109-18	69
406	Inherited Cancer Syndromes. 2004 ,	1
405	Therapeutic options for variant renal cancer: a true orphan disease. 2004 , 10, 6393S-6S	13
404	Linking human genetics with molecular medicine: will hereditary renal cancer play a major role?. 2004 , 3, 441-6	1
403	Molecular Targeting and Signal Transduction. 2004 ,	
402	Searching for the hereditary causes of renal-cell carcinoma. 2004 , 4, 381-93	151
401	The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. <i>Oncogene</i> , 2004 , 23, 5387-93	9.2 160
400	The Sema domain of Met is necessary for receptor dimerization and activation. 2004 , 6, 75-84	170

399	Focus on kidney cancer. 2004 , 6, 223-8		105
398	Hypoxic gene expression and metastasis. 2004 , 23, 293-310		185
397	Tyrosine kinase inhibitors in cancer therapy. 2004 , 37, 618-35		161
396	Genomic alterations in renal tumours: what have we learned in the era of comparative genomic hybridisation?. 2004 , 36, 51-7		4
395	Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. <i>Journal of Urology</i> , 2004 , 172, 1256-61	2.5	88
394	Genetic basis of cancer of the kidney: disease-specific approaches to therapy. 2004 , 10, 6282S-9S		159
393	Therapeutic targeting of the receptor tyrosine kinase Met. 2004 , 119, 121-38		13
392	MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. 2005 , 29, 544-9		55
391	Role of Hepatocyte Growth Factor and c-Met Receptor in Neoplastic Conditions of Salivary Glands. 2005 , 38, 25-30		9
390	Inhibition of hepatocyte growth factor induction in human dermal fibroblasts by tryptanthrin. 2005 , 28, 260-6		36
389	Characterization of quantitative chromosomal abnormalities in renal cell carcinomas by interphase four-color fluorescence in situ hybridization. 2005 , 158, 110-8		20
388	Novel approaches in the therapy of metastatic renal cell carcinoma. 2005 , 23, 202-12		178
387	A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. 2005 , 11, 2312-9		114
386	Inhibition of the met receptor in mesothelioma. 2005 , 11, 8122-30		62
385	A molecular classification of papillary renal cell carcinoma. 2005 , 65, 5628-37		185
384	High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. 2005 , 97, 931-5		184
383	Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. 2005 , 5, 973-86		32
382	Molecular biology of malignant mesothelioma: a review. 2005 , 19, 997-1023, v		13

381	Regulation of the wild-type and Y1235D mutant Met kinase activation. 2005 , 44, 14110-9	9
380	Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. 2005 , 65, 1479-88	470
379	c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. 2005 , 225, 1-26	440
378	MET expression in sporadic renal cell carcinomas. 2006 , 21, 672-7	35
377	Oncogenes. 2006 ,	
376	Scatter Factors in Tumor Progression. 2006 , 111-142	
375	Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. 2006 , 107, 760-8	68
374	Identification of a novel germline MET mutation in dogs. 2006 , 37, 248-52	24
373	A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. 2006 , 24, 543-6	121
372	Spectrum of molecular alterations in colorectal, upper urinary tract, endocervical, and renal carcinomas arising in a patient with hereditary non-polyposis colorectal cancer. 2006 , 449, 238-43	22
371	Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma. 2006 , 164, 142-7	8
370	Genetic basis of cancer of the kidney. 2006 , 33, 544-51	36
369	The pathology of renal epithelial neoplasms. 2006 , 33, 534-43	109
368	Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. 2006 , 6, 197	50
367	Treatment outcome for metastatic papillary renal cell carcinoma patients. 2006 , 107, 2617-21	75
366	Molecular pathogenetics of renal cancer. 2006 , 26, 218-31	12
365	Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. 2006 , 66, 3699-705	76
364	Molecular biology of renal cell cancer and the identification of therapeutic targets. 2006 , 24, 5593-600	50

363	Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. 2006 , 24, 754-79	27
362	MET overexpression turns human primary osteoblasts into osteosarcomas. 2006 , 66, 4750-7	106
361	Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. 2006 , 66, 352-61	171
360	Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. 2006 , 103, 3563-8	63
359	The Met pathway: master switch and drug target in cancer progression. 2006 , 20, 1611-21	110
358	Targeting the c-Met signaling pathway in cancer. 2006 , 12, 3657-60	373
357	Cell Motility in Cancer Invasion and Metastasis. 2006 ,	5
356	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. 2007 , 104, 20932-7	1395
355	Tyrosine kinase mutations in human cancer. 2007 , 7, 77-84	53
354	Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis. 2007 , 22, 2052-5	18
353	Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. 2007 , 13, 671s-679s	113
352	Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors. 2007 , 6, 1460-6	24
351	Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. 2007 , 248, 219-28	140
350	Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. <i>Oncogene</i> , 2007 , 26, 3440-9	9.2 40
349	Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. 2007 , 99, 1223-9	18
348	Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil. 2007 , 51, 1625-31; discussion 1631-2	21
347	Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. 2007 , 52, 1147-55	55
346	c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. 2007 , 9, 102-8	107

345	Renal cancer. 2007 , 64, 247-62		23
344	The Met tyrosine kinase receptor in development and cancer. 2008 , 27, 85-94		257
343	Expression and mutational analysis of MET in human solid cancers. 2008 , 47, 1025-37		246
342	Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase. 2008 , 18, 1945-51		53
341	Silencing the MET oncogene leads to regression of experimental tumors and metastases. <i>Oncogene</i> , 2008 , 27, 684-93	9.2	113
340	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. 2008 , 99, 911-22		145
339	Prognostic factors in a prospective series of papillary renal cell carcinoma. 2008 , 102, 697-702		36
338	Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. 2008 , 99, 2280-5		152
337	Lack of oncogenic mutations in the c-Met catalytic tyrosine kinase domain in acral lentiginous melanoma. 2008 , 47, 1327-9		2
336	Genetics and epigenetics of renal cell cancer. 2008 , 1785, 133-55		68
335	Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. 2008 , 8, 895-905		7
334	Genética molecular del cáncer renal: utilidad en pronóstico y posibilidades terapéuticas. 2008 , 1, 29-34		
333	Molecular biology of renal-cell carcinoma. 2008 , 6, 30-34		1
332	c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. 2008 , 265, 258-69		153
331	Molecular cancer therapy: can our expectation be MET?. <i>European Journal of Cancer</i> , 2008 , 44, 641-51	7.5	104
330	Carcinomas renales con papilas. 2008 , 41, 99-107		
329	Carcinomas renales con células claras. 2008 , 41, 169-182		2
328	Pathologic features of renal cortical tumors. 2008 , 35, 551-61; v		28

327	Concise handbook of familial cancer susceptibility syndromes - second edition. 2008 , 1-93	136
326	c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. 2008 , 283, 2675-83	121
325	Targeting the c-MET signaling pathway for cancer therapy. 2008 , 17, 997-1011	112
324	Molecular targeting agents in renal cell carcinoma: present strategies and future perspectives. 2008 , 14, 1058-77	6
323	Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. 2008 , 8, 779-90	41
322	The Fathers of Italian Histology. 2009 , 51, 1	4
321	New treatments for renal cell carcinoma: targeted therapies. 2009 , 7, 645-56	14
320	Targeting the Met signaling pathway in renal cancer. 2009 , 9, 785-93	60
319	Renal Cell Carcinoma. 2009 ,	3
318	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. 2009 , 4, 5-11	230
317	Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models. 2009 , 8, 1119-25	12
316	Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. 2009 , 15, 1162-9	139
315	SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. 2009 , 8, 3181-90	105
314	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. 2009 , 69, 4885-93	403
313	Hereditary kidney cancer: unique opportunity for disease-based therapy. 2009 , 115, 2252-61	89
312	Carcinomes à cellules rénales: de la pathologie aux voies moléculaires de la carcinogénèse. 2009 , 11, 254-259	
311	The MET axis as a therapeutic target. 2009 , 3, 109-118	28
310	Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. 2009 , 96, 858-74	39

309	Pathologic Features of Adult Renal Cortical Tumors. 2009 , 2, 1-25			1
308	Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. 2009 , 48, 5339-49			82
307	Molecular Biology. 2009 , 85-120			
306	Renal cell carcinoma: recent advances in genetics and imaging. 2009 , 30, 315-25			28
305	Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. 2009 , 10, 709-17			97
304	Recent advances in the systemic treatment of metastatic papillary renal cancer. 2009 , 9, 373-9			25
303	Targeted therapies in the treatment of advanced renal cell carcinoma. 2009 , 4, 146-56			7
302	Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. 2010 , 16, 1396-409			9
301	Molecular basis for the treatment of renal cell carcinoma. 2010 , 12, 15-21			15
300	Chromosomal abnormalities of clear cell renal cell carcinoma: frequent gain of chromosome 7. 2010 , 60, 9-13			19
299	Papillary renal cell-like carcinoma in a retroperitoneal teratoma. 2010 , 60, 581-5			4
298	Hereditary renal cancer syndromes: an update of a systematic review. 2010 , 58, 701-10			75
297	Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. 2010 , 199, 128-33			41
296	Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma. 2010 , 10, 46			38
295	Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. <i>Oncogene</i> , 2010 , 29, 5241-53	9.2		50
294	Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. <i>PLoS ONE</i> , 2010 , 5, e13586	3.7		10
293	MET receptor sequence variants R970C and T992I lack transforming capacity. 2010 , 70, 6233-7			63
292	Signaling pathways in renal cell carcinoma. 2010 , 10, 658-64			145

291	Mechanisms of Oncogenesis. 2010 ,		3
290	Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. 2010 , 16, 699-710		144
289	The Scientific Basis of Urology. 2010 ,		9
288	Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. 2010 , 16, 3581-93		34
287	Targeting the HGF/c-Met axis: state of play. 2010 , 9, 1077-9		34
286	Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers. 2010 , 4, 149-70		6
285	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. 2010 , 70, 7580-90		144
284	Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma. 2010 , 130, 901-3		17
283	[Papillary renal cell carcinoma: morphological subtypes, clinical and histopathological considerations]. 2010 , 20, 393-401		2
282	Molecular diagnosis and therapy of kidney cancer. 2010 , 61, 329-43		135
281	Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. 2010 , 289, 228-36		20
280	Targeting the HGF/Met signalling pathway in cancer. <i>European Journal of Cancer</i> , 2010 , 46, 1260-70	7.5	164
279	Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. 2010 , 2, 59		56
278	The genetic basis of kidney cancer: a metabolic disease. 2010 , 7, 277-85		516
277	The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt. 2011 , 35, 79-86		
276	An overview of the c-MET signaling pathway. 2011 , 3, S7-S19		492
275	Development of c-MET pathway inhibitors. 2011 , 20, 1225-41		51
274	Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. 2011 , 25, 853-69		20

273	Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. 2011 , 6, S1810-1		6
272	MET (met proto-oncogene (hepatocyte growth factor receptor)). 2011 ,		
271	Familial renal cancer: molecular genetics and surgical management. 2011 , 2011, 658767		18
270	[MET: new target, new combinations]. 2011 , 98, 689-96		0
269	Targeting the Hedgehog and Notch signaling pathways. 2011 , 6, S1820-1		
268	Differential diagnosis of renal tumors with papillary architecture. 2011 , 18, 120-32		55
267	Knowledge of hereditary renal cancer syndromes: a pending issue for oncologists. 2011 , 22 Suppl 1, S15-20		4
266	Repeat partial nephrectomy: surgical, functional and oncological outcomes. <i>Current Opinion in Urology</i> , 2011 , 21, 368-75	2.8	17
265	HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. 2011 , 12, 2045-58		25
264	Renal cell carcinoma. 2010 , 9, 461-73		283
263	A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. 2011 , 108, 679-86		47
262	Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. 2011 , 10, 2298-308		847
261	Clonal trisomies 7,10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney. 2011 , 459, 457-63		33
260	Impact of genetics on the diagnosis and treatment of renal cancer. 2011 , 12, 47-55		17
259	Genetically informed lung cancer medicine. 2011 , 223, 230-40		53
258	c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. 2011 , 54, 879-89		148
257	Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. <i>Modern Pathology</i> , 2011 , 24, 1146-55	9.8	68
256	A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. 2011 , 17, 7127-38		161

255	Targeting the phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer. 2011 , 6, S1805-7		3
254	A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. 2011 , 71, 5255-64		95
253	c-MET as a potential therapeutic target and biomarker in cancer. 2011 , 3, S21-35		261
252	Tumor biology and prognostic factors in renal cell carcinoma. 2011 , 16 Suppl 2, 4-13		97
251	Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. 2011 , 108, 1439-44		72
250	The role of the c-Met pathway in lung cancer and the potential for targeted therapy. 2011 , 3, 171-84		93
249	Cancer genes in lung cancer: racial disparities: are there any?. 2012 , 3, 467-80		92
248	Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma. 2012 , 199, W554-64		10
247	Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. 2012 , 22, 2089-100		162
246	Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. <i>Modern Pathology</i> , 2012 , 25, 122-30	9.8	22
245	The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. 2012 , 18, 6155-68		12
244	Targeting the HGF/Met signaling pathway in cancer therapy. 2012 , 16, 553-72		162
243	The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. 2012 , 287, 39812-23		16
242	Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. 2012 , 17, 46-54		139
241	Therapeutic potential of c-MET inhibitors: background and clinical data. 2012 , 2, 301-315		0
240	MET: a promising anticancer therapeutic target. 2012 , 9, 314-26		237
239	The transcriptional landscape and mutational profile of lung adenocarcinoma. 2012 , 22, 2109-19		435
238	Epidemiology, Aetiology, and Pathogenesis of Renal Cell Carcinoma. 2012 , 11, 52-59		29

237	A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. 2012 , 62, 1013-9	117
236	RET protein expression in papillary renal cell carcinoma. 2012 , 30, 900-5	12
235	Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma. 2012 , 11, 535-7	13
234	Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. 2012 , 12, 310	23
233	SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer. 2012 , 11, 49	25
232	HSP90 inhibitors for cancer therapy and overcoming drug resistance. 2012 , 65, 471-517	59
231	C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma. 2012 , 213-238	
230	Kidney Cancer. 2012 ,	4
229	Case of hereditary papillary renal cell carcinoma. 2011 , 1,	1
228	Molecular Pathogenesis of Renal Cell Carcinoma: A Review. 2012 ,	1
227	Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. 2007 , 1, S13-20	6
226	Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. 2007 , 1, S21-7	14
225	Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. 2012 , 118, 4427-36	98
224	Renal cell carcinoma deep sequencing: recent developments. 2012 , 14, 240-8	11
223	Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. 2012 , 30, 518-23	15
222	Cancer Genomics. 2013 ,	4
221	Vesicle Trafficking in Cancer. 2013 ,	1
220	Cancer of the Kidney and Urogenital Tract. 2013 , 1-17	

219	Oncogene alterations in endometrial carcinosarcomas. 2013 , 44, 852-9		23
218	The effect of deposition Se on the mRNA expression levels of GPxs in goats from a Se-enriched county of China. 2013 , 156, 111-23		5
217	Renal tumors with clear cells. A review. 2013 , 209, 137-46		42
216	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. 2013 , 31, 181-6		336
215	Metabolism of kidney cancer: from the lab to clinical practice. 2013 , 63, 244-51		54
214	Targeting MET: why, where and how?. 2013 , 13, 511-8		35
213	New insights into the management of renal cell cancer. 2013 , 84, 22-31		16
212	MET gain in diffuse astrocytomas is associated with poorer outcome. 2013 , 23, 13-8		22
211	Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. 2013 , 31, 1405-14		162
210	An overview of renal cell cancer: pathology and genetics. 2013 , 23, 3-9		87
209	Familial Renal Cell Carcinoma. 2013 , 43-52		
208	Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer. 2013 , 15, 83-90		23
207	Optimal management of metastatic renal cell carcinoma: current status. 2013 , 73, 427-38		84
206	Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. 2013 , 18, 207-13		64
205	MET: a critical player in tumorigenesis and therapeutic target. 2013 , 5,		88
204	Reply to Distinct ALK-rearranged and VCL-negative papillary renal cell carcinoma variants in two adults without sickle cell trait <i>Modern Pathology</i> , 2013 , 26, 605-7	9.8	3
203	Differential diagnosis of renal tumors with clear cytoplasm: clinical relevance of renal tumor subclassification in the era of targeted therapies and personalized medicine. <i>Archives of Pathology and Laboratory Medicine</i> , 2013 , 137, 467-80	5	36
202	Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. 2013 , 19, 316-23		42

201	Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens. 2013 , 20, 245-63	33
200	From Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes: A Personal History. 2013 , 2, 1-86	
199	Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. 2013 , 19, 3345-52	139
198	The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. 2013 , 73, 7022-33	43
197	Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma. 2013 , 19, 299-306	9
196	Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. 2013 , 3, 978-92	63
195	c-Met function requires N-linked glycosylation modification of pro-Met. 2013 , 114, 816-22	21
194	CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma. 2013 , 8, 739-47	15
193	Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. 2013 , 18, 454-73	27
192	Nucleic Acid-Based Markers in Urologic Malignancies. 2014 , 63-128	
191	. 2014 ,	1
190	Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. 2014 , 46, 2127-32	21
189	Kinase Inhibitors in Cancer. 2014 ,	2
188	Met in urological cancers. <i>Cancers</i> , 2014 , 6, 2387-403	6.6 17
187	Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery. 2014 , 19, 1350-61	3
186	MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. 2014 , 20, 3411-21	108
185	Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. 2014 , 31, 761-9	15
184	A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers. 2014 , 15, 721-34	11

183	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. 2014 , 4, 194	18
182	Papillary renal cell carcinoma: current progress and future directions. 2014 , 12, 74-9	10
181	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. 2014 , 142, 316-38	148
180	Precision medicine for metastatic renal cell carcinoma. 2014 , 32, 5-15	14
179	Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. 2014 , 232, 32-42	39
178	Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. 2014 , 33, 1109-24	60
177	Hereditary kidney cancer syndromes. 2014 , 21, 81-90	93
176	Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma. 2015 , 106, 656-64	26
175	High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. 2015 , 25, 189-99	12
174	Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features. 2015 , 39, e1-e18	39
173	Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology. 2015 , 27, 217-23	33
172	Retrospective Review of MET Gene Mutations. 2015 , 2, 533-41	28
171	Renal Cell Carcinoma: Overview. 2015 , 337-344	
170	Targeting the MET pathway for potential treatment of NSCLC. 2015 , 19, 663-74	16
169	Kidney Cancer. 2015 ,	1
168	MET. 2015 , 1-14	
167	Amsterdam patient charter for global kidney cancer care. 2015 , 67, 354-5	
166	Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib. 2015 , 67, 353-4	7

165	A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. 2015 , 17, 70-87	305
164	Hereditary Kidney Cancer Syndromes. 2015 , 123-133	
163	MET: a new promising biomarker in non-small-cell lung carcinoma. 2015 , 16, 631-47	20
162	Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases. 2015 , 54, 369-82	34
161	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. 2015 , 102, 90-106	3
160	c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. 2015 , 15, 451	24
159	Adult Renal Cell Carcinoma: A Review of Established Entities from Morphology to Molecular Genetics. 2015 , 8, 587-621	32
158	Renal Cell Carcinoma. 2015 ,	
157	MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. 2015 , 13, e19-26	16
156	Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. 2015 , 47, 13-21	247
155	Genomic Applications in Pathology. 2015 ,	
154	Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?. 2016 , 7, 633-49	22
153	MET Inhibition in Clear Cell Renal Cell Carcinoma. 2016 , 7, 1205-14	16
152	Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. 2016 , 9, 5825-5837	20
151	A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors. 2016 , 139, 1851-63	15
150	[c-MET Oncogene in Renal Cell Carcinomas]. 2016 , 47, 475-479	0
149	In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. 2016 , 15, 1568-79	41
148	Genetic predisposition to kidney cancer. 2016 , 43, 566-574	77

147	Precision medicine from the renal cancer genome. 2016 , 12, 655-666		37
146	Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families. 2016 , 15, 677-87		3
145	Resistance to Tyrosine Kinase Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016 ,	0.3	1
144	MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis. 2016 , 9, ra62		20
143	Choosing the right cell line for renal cell cancer research. 2016 , 15, 83		129
142	Management of renal cell carcinoma in young patients and patients with hereditary syndromes. <i>Current Opinion in Urology</i> , 2016 , 26, 396-404	2.8	8
141	Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. <i>Current Opinion in Urology</i> , 2016 , 26, 383-7	2.8	14
140	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. 2016 , 14, 589-98		20
139	Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma. <i>Oncogene</i> , 2016 , 35, 5457-5467	9.2	24
138	Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease. 2016 , 209, 11-20		7
137	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. 2016 , 374, 135-45		753
136	[MET receptor inhibition: Hope against resistance to targeted therapies?]. 2017 , 104, 157-166		5
135	Molecular Genetics of Renal Cell Carcinoma. 2017 , 83-103		1
134	Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts. 2017 , 26, 548-555		8
133	Understanding c-MET signalling in squamous cell carcinoma of the head & neck. 2017 , 111, 39-51		32
132	New Targets in Non-Small Cell Lung Cancer. 2017 , 31, 113-129		16
131	MET. 2017 , 773-786		
130	Renal cell cancers: unveiling the hereditary ones and saving lives-a tailored diagnostic approach. 2017 , 49, 1507-1512		3

129	Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAB) in the Second- and Third-Line Non-Small Cell Lung Cancer. 2017 , 19, 527-533		6
128	Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure. 2017 ,		1
127	Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine. 2017 , 284, 333-351		33
126	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017 , 87, 147-163	7.5	74
125	Some thermodynamic considerations on low frequency electromagnetic waves effects on cancer invasion and metastasis. 2017 , 467, 289-295		10
124	Epidemiology of Renal Cell Carcinoma. 2017 , 313-334		
123	Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice. <i>Kidney Cancer</i> , 2017 , 1, 99-105	0.6	5
122	c-Met Onkogen bei Nierenzellkarzinomen. 2017 , 38, 381-385		
121	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. 2017 , 35, 2993-3001		112
120	Regulation of Signal Transduction in Human Cell Research. 2018 ,		
119	Morphological clues to the appropriate recognition of hereditary renal neoplasms. 2018 , 35, 184-192		2
118	Renal cell carcinoma for the nephrologist. 2018 , 94, 471-483		38
117	Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. 2018 , 44, 840-846		9
116	Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018 ,	0.3	1
115	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. 2018 , JCO2018792259		28
114	Receptor Tyrosine Kinase-Targeted Cancer Therapy. 2018 , 19,		103
113	Molecular Basics on Genitourinary Malignancies. 2018 , 1-15		
112	Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology. 2018 , 152, 188-197		11

111	Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. 2019 , 25-60	0
110	Molecular Basics on Genitourinary Malignancies. 2019 , 3-17	
109	Interactions between TGF- β type I receptor and hypoxia-inducible factor-1 mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma. 2019 , 18, 2141-2156	13
108	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. 2019 , 16, 655-673	12
107	Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study. 2019 , 12, 4195-4202	
106	Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas. 2019 , 26, 868-877	9
105	The significance of gene mutations across eight major cancer types. 2019 , 781, 88-99	8
104	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys". 2019 , 20,	27
103	C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. 2019 , 8,	14
102	Papillary Renal Cell Carcinoma (PRCC): An Update. 2019 , 26, 124-132	40
101	Inherited kidney cancer syndromes. <i>Current Opinion in Urology</i> , 2019 , 29, 334-343	2.8 9
100	Further Evidence for the Implication of the MET Gene in Non-Syndromic Autosomal Recessive Deafness. 2019 , 84, 109-116	1
99	Genetics of Renal Cell Carcinoma. 2019 , 39-54	
98	Diagnosis and Surgical Management of Renal Tumors. 2019 ,	1
97	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. 2020 , 26, 439-449	34
96	Meta-analysis of functional expression and mutational analysis of c-Met in various cancers. 2020 , 44, 100515	2
95	Renal Cell Tumors: Molecular Findings Reshaping Clinico-pathological Practice. 2020 , 51, 799-816	1
94	Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. 2020 , 7,	3

93	Design of Fluorescent Probes for Bioorthogonal Labeling of Carbonylation in Live Cells. 2020 , 10, 7668	4
92	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. 2020 , 6, 1247-1255	51
91	Targeting Dysregulation in Cancer. 2020 , 10, 922-934	26
90	MET-dependent solid tumours - molecular diagnosis and targeted therapy. 2020 , 17, 569-587	55
89	The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. 2020 , 8, 55	47
88	MET receptor in oncology: From biomarker to therapeutic target. 2020 , 147, 259-301	9
87	MET targeting: time for a rematch. <i>Oncogene</i> , 2020 , 39, 2845-2862	9.2 24
86	c-Met as a potential therapeutic target in triple negative breast cancer. 2020 , 295-326	1
85	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in -Mutant Lung Cancer. 2020 , 26, 2654-2663	103
84	MET somatic activating mutations are responsible for lymphovenous malformation and can be identified using cell-free DNA next generation sequencing liquid biopsy. 2021 , 9, 740-744	2
83	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. 2021 , 60, 434-446	1
82	Application of the ACMG/NSGC genetic referral guidelines for hereditary renal cell carcinoma at the University of Miami, from 2014 to 2017. 2021 , 185, 3012-3018	
81	Kidney cancer: from genes to therapy. 2021 , 45, 100773	1
80	Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease. 2021 ,	1
79	Prognostic and Therapeutic Potential of the OIP5 Network in Papillary Renal Cell Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6 0
78	Aberrant Activation of HGF/c-MET Signaling and Targeted Therapy in Squamous Cancer. 2011 , 91-111	1
77	Familial and Hereditary Syndromes in Renal Cell Cancer. 2020 , 35-48	2
76	Hereditary Renal Cell Carcinoma. 2017 , 19-82	1

75	Met Activation and Carcinogenesis. 2018 , 129-154		2
74	Malignant Renal Tumors. 2012 , 1413-1474.e33		25
73	Treatment of Advanced Renal Cell Carcinoma. 2012 , 1475-1491.e5		2
72	Renal Cancer. 2006 , 1087-1100		25
71	HISTOPATHOLOGY AND MOLECULAR GENETICS OF RENAL TUMORS: TOWARD UNIFICATION OF A CLASSIFICATION SYSTEM. <i>Journal of Urology</i> , 1999 , 1246-1258	2.5	2
70	Biological Significance of C-met Over Expression in Papillary Renal Cell Carcinoma. <i>Journal of Urology</i> , 2002 , 51-55	2.5	2
69	Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer.		0
68	Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. <i>Journal of Clinical Investigation</i> , 2002 , 109, 863-867	15.9	209
67	Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. <i>Journal of Clinical Investigation</i> , 2002 , 109, 863-7	15.9	97
66	Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays. <i>PLoS ONE</i> , 2011 , 6, e21260	3.7	8
65	Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients. <i>PLoS ONE</i> , 2015 , 10, e0143468	3.7	11
64	Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification. <i>Oncotarget</i> , 2017 , 8, 26281-26287	3.3	17
63	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015 , 6, 2604-14	3.3	27
62	Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities. <i>Oncotarget</i> , 2016 , 7, 38091-38104	3.3	4
61	MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. <i>Annals of Translational Medicine</i> , 2017 , 5, 2	3.2	32
60	MET in human cancer: germline and somatic mutations. <i>Annals of Translational Medicine</i> , 2017 , 5, 205	3.2	33
59	The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer. <i>Current Signal Transduction Therapy</i> , 2011 , 6, 146-151	0.8	18
58	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. <i>Programme Grants for Applied Research</i> , 2018 , 6, 1-528	1.5	3

57	Biology of MET: a double life between normal tissue repair and tumor progression. <i>Annals of Translational Medicine</i> , 2015 , 3, 82	3.2	32
56	Recent developments in the pathology of renal tumors: morphology and molecular characteristics of select entities. <i>Archives of Pathology and Laboratory Medicine</i> , 2009 , 133, 1026-32	5	34
55	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). <i>European Journal of Cancer</i> , 2021 , 158, 1-11	7.5	0
54	SPORADIC BILATERAL PAPILLARY RENAL CARCINOMA EXHIBITING C-MET MUTATION IN THE LEFT KIDNEY TUMOR. <i>Journal of Urology</i> , 2000 , 1241	2.5	
53	Familien Nierenkarzinom. 2001 , 439-469		
52	Nierenzellkarzinome. 2002 , 257-289		
51	Genetic Aspects of Urologic Malignancies. 2004 , 205-240		
50	Metastasis.		
49	Molecular genetics and pathogenesis of renal cancer. 2007 , 23-40		
48	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma. 2009 , 321-334		
47	The Role of Oncogene Activation in Tumor Progression. 2010 , 19-41		
46	The Molecular Genetics and Pathology of Renal Cell Carcinoma. 2010 , 360-373		
45	Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations. 2012 , 249-264		
44	Molecular Characterization of Renal Cell Carcinoma. 2012 , 91-111		0
43	Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma. 2012 , 289-324		
42	The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies. 2012 , 3-25		1
41	Renal Neoplasia. 2012 , 1508-1535		
40	RTKs as Models for Trafficking Regulation: c-Met/HGF Receptor-c-Met Signalling in Cancer Location Counts. 2013 , 261-277		

- 39 Molecular Biology and Genetics. **2013**, 19-37
- 38 Familial and Hereditary Syndromes. **2013**, 39-50
- 37 Cancer of the Kidney and Urogenital Tract. **2014**,
- 36 Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to the Clinic. **2015**, 435-464
- 35 Genetics and Genito-Urinary Cancer. **2015**, 51-69
- 34 Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets. **2015**, 15-38 1
- 33 The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma. **2015**, 303-318
- 32 Variant Renal Carcinoma Histologies: Therapeutic Considerations. **2015**, 345-364
- 31 Familial Forms of Renal Cell Carcinoma and Associated Syndromes. **2016**, 81-95
- 30 Papillary Renal Cell Carcinoma. **2016**, 80-89
- 29 Papillary Renal Carcinoma. **2016**, 1-29
- 28 Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. *Resistance To Targeted Anti-cancer Therapeutics*, **2016**, 27-107 0.3
- 27 Targeted therapy in cancer. *Oncolog-Hematolog Ro*, **2018**, 3, 13 0
- 26 Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis. *Resistance To Targeted Anti-cancer Therapeutics*, **2018**, 67-87 0.3
- 25 Molecular Biology and Genetics of Renal Cell Carcinoma. **2020**, 19-33
- 24 What molecular and genetic changes are characteristic of renal tumors? Based on the new knowledge, is molecular targeting feasible?. **2008**, 117-124
- 23 Renal Cell Cancer. **2006**, 789-812
- 22 Renal Cell Carcinoma. **2008**, 241-261

21	Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. <i>Reviews in Urology</i> , 2007 , 9, 47-56	1	21
20	Genetic and epigenetic alterations during renal carcinogenesis. <i>International Journal of Clinical and Experimental Pathology</i> , 2010 , 4, 58-73	1.4	45
19	Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. <i>American Journal of Translational Research (discontinued)</i> , 2013 , 5, 200-11	3	30
18	c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer. <i>Translational Oncogenomics</i> , 2006 , 1, 11-8		6
17	Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2019 , 17, 94-104	0.1	
16	Roles of MET in Human Cancer.. <i>Clinica Chimica Acta</i> , 2021 , 525, 69-69	6.2	0
15	Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. <i>Human Mutation</i> , 2021 ,	4.7	0
14	The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis.. <i>PLoS Pathogens</i> , 2022 , 18, e1010247	7.6	
13	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.. <i>Modern Pathology</i> , 2021 ,	9.8	1
12	Hereditary Renal Cancer Predisposition Syndromes. 2022 , 15-33		
11	Hereditary Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022 , 1-11	0.6	
10	Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy. 2005 , 531-552		
9	Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. <i>European Journal of Cancer</i> , 2022 , 170, 158-168	7.5	
8	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41,	12.8	1
7	Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44. <i>Cancers</i> , 2022 , 14, 3444	6.6	1
6	Major heritable renal cell carcinoma syndromes: novel treatment options and future perspectives. <i>Current Opinion in Urology</i> , Publish Ahead of Print,	2.8	
5	The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents. 10,		2
4	MET gene amplification is a mechanism of resistance to entrectinib in ROS1 + NSCLC.		0

3	Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches. 2022 , 2, 555-573	0
2	Radiogenomics in Renal Cancer Management: Current Evidence and Future Prospects. 2023 , 24, 4615	1
1	Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic Targets. 2023 ,	0